| scholarly article | Q13442814 |
| P50 | author | Elizabeth J Shpall | Q87373605 |
| P2093 | author name string | Katayoun Rezvani | |
| Partow Kebriaei | |||
| Amin Alousi | |||
| LaQuisa Hill | |||
| Rohtesh Mehta | |||
| P2860 | cites work | The Janus kinases (Jaks) | Q21194856 |
| Rocks: multifunctional kinases in cell behaviour | Q24303641 | ||
| Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation | Q24626051 | ||
| Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease | Q24626202 | ||
| Novel agents in the treatment of multiple myeloma: a review about the future | Q26745924 | ||
| CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition | Q26777563 | ||
| IL-17 and Th17 Cells | Q27860566 | ||
| Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases | Q28131652 | ||
| Pentostatin in steroid-refractory acute graft-versus-host disease | Q28245825 | ||
| Human mesenchymal stem cells modulate allogeneic immune cell responses | Q28288692 | ||
| Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 | ||
| Pluripotency of mesenchymal stem cells derived from adult marrow | Q29617959 | ||
| Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota | Q29618128 | ||
| Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells | Q29618766 | ||
| Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli | Q29618769 | ||
| Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification | Q30235611 | ||
| Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease | Q33340454 | ||
| Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease | Q33364353 | ||
| Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. | Q33369676 | ||
| Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease | Q33378052 | ||
| High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma | Q33378693 | ||
| Improved survival after acute graft-versus-host disease diagnosis in the modern era. | Q33816027 | ||
| Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation | Q33838584 | ||
| Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro | Q33942128 | ||
| Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice | Q33987268 | ||
| The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. | Q34047880 | ||
| Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors | Q34079116 | ||
| The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland | Q34082721 | ||
| Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice | Q34090173 | ||
| Treatment of chronic graft-versus-host disease with bortezomib | Q34137032 | ||
| Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics | Q34144161 | ||
| Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation | Q34162461 | ||
| cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity | Q34192806 | ||
| Graft-versus-host disease treatment: predictors of survival | Q34205096 | ||
| Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD | Q34292984 | ||
| Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | Q34301568 | ||
| Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation | Q34311369 | ||
| Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib | Q34332019 | ||
| α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics | Q34431458 | ||
| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 | ||
| R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation | Q34562439 | ||
| Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism | Q34601386 | ||
| IL-17 and the Th17 lineage in systemic lupus erythematosus | Q34807773 | ||
| Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD | Q34974093 | ||
| Long-term survival and late deaths after allogeneic hematopoietic cell transplantation | Q35023409 | ||
| A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study | Q35120338 | ||
| Molecular actions of sirolimus: sirolimus and mTor | Q35125798 | ||
| Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo | Q35126283 | ||
| Ibrutinib treatment ameliorates murine chronic graft-versus-host disease | Q35140097 | ||
| Aberrant B-cell homeostasis in chronic GVHD | Q35171251 | ||
| A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality | Q35177453 | ||
| Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids | Q35193740 | ||
| Treatment of chronic graft-versus-host disease: Past, present and future | Q35524687 | ||
| Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model | Q35525740 | ||
| Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen | Q35553626 | ||
| Chronic graft-vs-host disease | Q35587714 | ||
| Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation | Q35673668 | ||
| IL-2, regulatory T cells, and tolerance | Q35700529 | ||
| Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance | Q35703487 | ||
| A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease | Q35737769 | ||
| Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice | Q35766798 | ||
| Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans | Q35776453 | ||
| Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease | Q35784522 | ||
| How I treat refractory acute GVHD. | Q35828633 | ||
| Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease | Q35848361 | ||
| Increased BCR responsiveness in B cells from patients with chronic GVHD. | Q37670076 | ||
| Glucocorticoid-refractory acute graft-versus-host disease | Q37680126 | ||
| Treatment of graft-versus-host-disease with mesenchymal stromal cells | Q37828156 | ||
| The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. | Q37851519 | ||
| Proteasome inhibitors in multiple myeloma: 10 years later | Q38014395 | ||
| IL-22, not simply a Th17 cytokine | Q38081171 | ||
| Monoclonal antibodies in treatment of multiple sclerosis | Q38133865 | ||
| Therapeutic opportunities of the IL-22-IL-22R1 system | Q38174792 | ||
| The role of integrin antagonists in the treatment of inflammatory bowel disease | Q38257410 | ||
| Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis | Q38696262 | ||
| Current and emerging therapeutic targets for IBD. | Q38763559 | ||
| Emerging drugs for graft-versus-host disease | Q38786084 | ||
| Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease | Q38803321 | ||
| Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence | Q38821389 | ||
| New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease | Q38849186 | ||
| Mechanistic approaches for the prevention and treatment of chronic GVHD. | Q39002166 | ||
| Novel targets in the treatment of chronic graft-versus-host disease | Q39023963 | ||
| A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis | Q39485380 | ||
| Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas | Q40550215 | ||
| Isoform-specific targeting of ROCK proteins in immune cells | Q40967956 | ||
| Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years | Q40989464 | ||
| IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation | Q41049735 | ||
| Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results | Q41387926 | ||
| Expression of CD30 in patients with acute graft-versus-host disease | Q41984840 | ||
| NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. | Q42118143 | ||
| L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease | Q42234577 | ||
| Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease | Q42336324 | ||
| Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. | Q42737499 | ||
| Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease | Q42772274 | ||
| Sirolimus for treatment of steroid-refractory acute graft-versus-host disease | Q43228479 | ||
| The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 | ||
| Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems | Q44097093 | ||
| Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease | Q44162081 | ||
| Proteasome inhibition profoundly affects activated human B cells. | Q44467702 | ||
| Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome | Q44521800 | ||
| Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. | Q44614482 | ||
| LPAM (α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease | Q44620762 | ||
| Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab | Q44761574 | ||
| Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease | Q44925138 | ||
| Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant | Q44925296 | ||
| Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies | Q45124604 | ||
| Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin | Q46361757 | ||
| Ibrutinib for chronic graft-versus-host disease after failure of prior therapy | Q46428638 | ||
| Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. | Q46460065 | ||
| The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis | Q46549173 | ||
| Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity | Q35848453 | ||
| High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT | Q35849935 | ||
| Tolerance, not immunity, crucially depends on IL-2. | Q35877199 | ||
| Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease | Q35892249 | ||
| Advances in understanding the pathogenesis of graft-versus-host disease | Q35971439 | ||
| Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease | Q35971980 | ||
| First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 | ||
| Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation | Q36130498 | ||
| B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways | Q36250962 | ||
| Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. | Q36259898 | ||
| A case for regulatory B cells | Q36360842 | ||
| IFNγR signaling mediates alloreactive T-cell trafficking and GVHD | Q36395621 | ||
| Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration | Q36483525 | ||
| Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation | Q36571580 | ||
| Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect | Q36622195 | ||
| Regulatory T cells and transplantation tolerance | Q36630515 | ||
| The JAK-STAT signaling pathway: input and output integration | Q36740971 | ||
| What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score | Q36846650 | ||
| Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. | Q36851405 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease | Q36940174 | ||
| Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors | Q36951734 | ||
| Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 | ||
| Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease | Q37076418 | ||
| Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial | Q37113099 | ||
| Cytokine signaling modules in inflammatory responses | Q37133450 | ||
| Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. | Q37152028 | ||
| Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice | Q37191056 | ||
| The role of IL-21 in regulating B-cell function in health and disease. | Q37211251 | ||
| An essential role for the IL-2 receptor in Treg cell function | Q37351745 | ||
| Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. | Q37376599 | ||
| Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. | Q37468247 | ||
| New perspectives on the biology of acute GVHD. | Q37641063 | ||
| Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease | Q46617730 | ||
| An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus | Q46625173 | ||
| Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. | Q47365613 | ||
| Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. | Q47804385 | ||
| Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. | Q50855347 | ||
| Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. | Q52621229 | ||
| Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease. | Q52994863 | ||
| Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. | Q53990752 | ||
| Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. | Q54035816 | ||
| Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. | Q54254821 | ||
| Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. | Q54485643 | ||
| Chronic graft-versus-host disease | Q56340012 | ||
| CD4+CD25high regulatory cells in human peripheral blood | Q56905059 | ||
| Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10 | Q57194209 | ||
| IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect | Q57194234 | ||
| B-cell involvement in chronic graft-versus-host disease | Q57676591 | ||
| Infliximab treatment for steroid-refractory acute graft-versus-host disease | Q59281270 | ||
| Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population | Q59713756 | ||
| Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease | Q63197317 | ||
| Blocking L-selectin and alpha4-integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease | Q73444018 | ||
| Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease | Q73613538 | ||
| CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role | Q73644574 | ||
| Inhibition of NF-kappaB-dependent T cell activation abrogates acute allograft rejection | Q77137086 | ||
| Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease | Q77754791 | ||
| Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | Q80177840 | ||
| Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib | Q80288306 | ||
| Donor APCs are required for maximal GVHD but not for GVL | Q80402910 | ||
| Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation | Q80984434 | ||
| Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation | Q81298136 | ||
| Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease | Q81317575 | ||
| Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium | Q82092596 | ||
| Chronic graft-versus-host disease | Q82325119 | ||
| IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis | Q83163682 | ||
| Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective | Q83940125 | ||
| First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells | Q84135263 | ||
| Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report | Q84931084 | ||
| Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease | Q86499606 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| P433 | issue | 1 | |
| P921 | main subject | Chronic graft versus host disease | Q111329725 |
| P304 | page(s) | 21-46 | |
| P577 | publication date | 2017-11-28 | |
| P1433 | published in | Therapeutic advances in hematology | Q26842172 |
| P1476 | title | New and emerging therapies for acute and chronic graft versus host disease | |
| P478 | volume | 9 |
| Q92354151 | Alpha-1 Antitrypsin-Expressing Mesenchymal Stromal Cells Confer a Long-Term Survival Benefit in a Mouse Model of Lethal GvHD |
| Q64900793 | Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. |
| Q91907363 | Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required |
| Q89820696 | Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD) |
| Q57167371 | Extracorporeal Photopheresis-An Overview |
| Q90058555 | Glucocorticoids delivered by inorganic-organic hybrid nanoparticles mitigate acute graft-versus-host disease and sustain graft-versus-leukemia activity |
| Q59800879 | Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD |
| Q92318457 | The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells |
Search more.